Rockwell Medical (RMTI) Income from Continuing Operations (2010 - 2026)
Rockwell Medical's (RMTI) quarterly Income from Continuing Operations came in at 7211000.0 in Q1 2026, down 290.63% YoY from 3782752.49 in Q1 2025, and down 336.77% on a QoQ basis from 1651000.0 in Q4 2025.
Rockwell Medical (RMTI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Rockwell Medical (RMTI) has 17 years of Income from Continuing Operations data on file, last reported at 7211000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 290.63% year-over-year to 7211000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13539000.0 (down 2145.27% YoY) and the FY2025 annual result came in at 11353000.0, up 86.57% from the prior year.
- Income from Continuing Operations fell to 7211000.0 in Q1 2026, from 1651000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1517000.0 in Q3 2024 to a low of 7211000.0 in Q1 2026.
- A 5-year average of 2531058.82 and a median of 1896000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 170.82% — and 2025, when it plunged 2748.98%.
- Tracing RMTI's Income from Continuing Operations over 5 years: stood at 1896000.0 in 2022, then gained by 14.93% to 1613000.0 in 2023, then soared by 76.94% to 372000.0 in 2024, then plunged by 343.82% to 1651000.0 in 2025, then tumbled by 336.77% to 7211000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7211000.0 (Q1 2026), 1651000.0 (Q4 2025), and 2081000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Rockwell Medical | 30.62 Mn | 5.82 Mn | 3.24 Mn | -1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.32 Mn |
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | -1.65 Mn |
| Sep 30, 2025 | -2.08 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Mar 31, 2025 | -1.85 Mn |
| Dec 31, 2024 | -372,000.00 |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 98,000.00 |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -1.61 Mn |
| Sep 30, 2023 | -2.14 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -1.79 Mn |
| Dec 31, 2022 | -1.90 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -4.97 Mn |
| Mar 31, 2022 | -7.17 Mn |
| Dec 31, 2021 | -8.41 Mn |
| Sep 30, 2021 | -7.58 Mn |